Udg Healthcare (LON:UDG) was upgraded by equities research analysts at Numis Securities to a “hold” rating in a report released on Thursday, ThisIsMoney.Co.Uk reports.
Several other research analysts also recently commented on UDG. Peel Hunt reaffirmed a “buy” rating on shares of Udg Healthcare in a report on Thursday, May 2nd. Liberum Capital reaffirmed a “buy” rating and set a GBX 884 ($11.55) target price on shares of Udg Healthcare in a report on Monday, February 4th. Finally, Barclays raised Udg Healthcare to an “overweight” rating and cut their target price for the stock from GBX 770 ($10.06) to GBX 720 ($9.41) in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Udg Healthcare currently has an average rating of “Buy” and an average price target of GBX 780.57 ($10.20).
LON UDG opened at GBX 665 ($8.69) on Thursday. The company has a debt-to-equity ratio of 27.53, a quick ratio of 1.80 and a current ratio of 2.02. Udg Healthcare has a twelve month low of GBX 545 ($7.12) and a twelve month high of GBX 950.50 ($12.42). The firm has a market cap of $1.65 billion and a P/E ratio of 443.33.
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.